Gluformin Combi

Gluformin Combi is a prescription oral medication that combines metformin hydrochloride and sitagliptin hydrochloride. It is formulated as a tablet (strength not specified) and is marketed in the European Union. The product belongs to the biguanide and DPP‑4 inhibitor classes and is used to improve glycemic control in adults with type 2 diabetes mellitus. It works by reducing hepatic glucose output and enhancing insulin secretion.

Gluformin Combi is indicated for the management of type 2 diabetes mellitus when diet, exercise, and monotherapy are insufficient to achieve target blood glucose levels. It may be prescribed as part of a comprehensive treatment plan that includes lifestyle modification.

- Adjunct to diet and exercise for adults with type 2 diabetes. - Combination therapy when metformin alone does not provide adequate glycemic control. - Use in patients requiring both reduced hepatic glucose production and enhanced insulin secretion. - Suitable for individuals with stable renal function who meet metformin prescribing criteria. - Can be considered when a once‑daily oral regimen is preferred.

The safety profile of Gluformin Combi reflects the combined effects of metformin and sitagliptin. Reported adverse events are categorized as common or serious based on frequency and clinical impact.

Common: - Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea. - Headache or dizziness. - Upper respiratory tract infection symptoms. - Mild hypoglycemia, especially when used with other glucose‑lowering agents.

Serious: - Lactic acidosis, a rare but life‑threatening condition associated with metformin. - Pancreatitis, presenting with severe abdominal pain and elevated enzymes. - Severe hypersensitivity reactions, including skin rash or angioedema. - Significant renal impairment leading to drug accumulation.

Before initiating Gluformin Combi, clinicians should evaluate patient-specific factors and monitor for potential risks associated with both components of the combination.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Avoid use in patients with a history of lactic acidosis. - Monitor hepatic function, as liver disease may increase the risk of lactic acidosis. - Use caution in individuals with a history of pancreatitis when sitagliptin is included. - Consider dose adjustment in elderly patients due to altered pharmacokinetics. - Pregnancy and breastfeeding status should be reviewed; safety data are limited. - Regularly review concomitant medications that may affect glucose control.

Gluformin Combi may interact with other medicines, influencing its efficacy or safety. Interactions are grouped by the level of clinical concern.

Avoid: - Concurrent use of other biguanides or high‑dose metformin, increasing risk of lactic acidosis. - Strong CYP3A4 inhibitors that may raise sitagliptin plasma concentrations. - Iodinated contrast agents in patients with reduced renal function.

Use with caution: - Diuretics that may affect renal clearance of metformin. - Beta‑blockers or other antihypertensives that mask hypoglycemia symptoms. - Insulin or sulfonylureas, which can potentiate hypoglycemia. - Alcohol intake, which may predispose to lactic acidosis.